Biogen shares are trading lower after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.
Portfolio Pulse from Benzinga Newsdesk
Biogen shares are trading lower after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.
July 26, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen shares are trading lower due to the European Medicines Agency's negative opinion on the Marketing Authorization Approval for lecanemab.
The negative opinion from the European Medicines Agency on lecanemab's Marketing Authorization Approval is a significant regulatory setback for Biogen, likely leading to a short-term decline in its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100